Clinical trials
Terminated Arthritis, Rheumatoid trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
262 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 6 |
| 2003 | 5 |
| 2004 | 9 |
| 2005 | 7 |
| 2006 | 14 |
| 2007 | 14 |
| 2008 | 15 |
| 2009 | 7 |
| 2010 | 15 |
| 2011 | 21 |
| 2012 | 24 |
| 2013 | 16 |
| 2014 | 17 |
| 2015 | 16 |
| 2016 | 14 |
| 2017 | 12 |
| 2018 | 5 |
| 2019 | 10 |
| 2020 | 9 |
| 2021 | 5 |
| 2022 | 8 |
| 2023 | 7 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 262 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 13 |
| DePuy International | 11 |
| GlaxoSmithKline | 10 |
| Zimmer Biomet | 9 |
| Eli Lilly and Company | 8 |
| Amgen | 7 |
| Merck Sharp & Dohme LLC | 7 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 7 |
| Pfizer | 7 |
| AstraZeneca | 6 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arthritis, Rheumatoid | 262 |
| Osteoarthritis | 42 |
| Osteonecrosis | 29 |
| Arthritis | 19 |
| Hip Dislocation, Congenital | 11 |
| Autoimmune Diseases | 8 |
| Inflammation | 8 |
| Spondylitis, Ankylosing | 8 |
| Arthritis, Psoriatic | 7 |
| Collagen Diseases | 7 |
Trials
Showing 51 to 75 of 262. Each trial links to its page on Pharma Observatory.
162 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.